IP Verse

Novel Kif5B-Ret Fusion Molecules And Uses Thereof - EP2748192

The patent EP2748192 was granted to Foundation Medicine on Apr 20, 2022. The application was originally filed on Aug 23, 2012 under application number EP12825669A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2748192

FOUNDATION MEDICINE
Application Number
EP12825669A
Filing Date
Aug 23, 2012
Status
Patent Maintained As Amended
Mar 18, 2022
Publication Date
Apr 20, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANAug 14, 2019CARPMAELS & RANSFORDADMISSIBLE
JAMES POOLEAug 14, 2019CARPMAELS & RANSFORDWITHDRAWN

Patent Citations (74) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO1996US03651
DESCRIPTIONEP0125023
DESCRIPTIONEP0171496
DESCRIPTIONEP0173494
DESCRIPTIONEP0184187
DESCRIPTIONEP0264166
DESCRIPTIONKR20040075272
DESCRIPTIONUS2003143204
DESCRIPTIONUS2003166282
DESCRIPTIONUS2003224432
DESCRIPTIONUS2004038278
DESCRIPTIONUS2004086884
DESCRIPTIONUS2006246497
DESCRIPTIONUS2006275779
DESCRIPTIONUS2007087362
DESCRIPTIONUS2007194225
DESCRIPTIONUS4366241
DESCRIPTIONUS4376110
DESCRIPTIONUS4458066
DESCRIPTIONUS4517288
DESCRIPTIONUS4816567
DESCRIPTIONUS4837168
DESCRIPTIONUS4868103
DESCRIPTIONUS4873316
DESCRIPTIONUS4987071
DESCRIPTIONUS5093246
DESCRIPTIONUS5116742
DESCRIPTIONUS5223409
DESCRIPTIONUS5225539
DESCRIPTIONUS5491224
DESCRIPTIONUS5545806
DESCRIPTIONUS5547835
DESCRIPTIONUS5569825
DESCRIPTIONUS5605798
DESCRIPTIONUS5625126
DESCRIPTIONUS5631169
DESCRIPTIONUS5633425
DESCRIPTIONUS5661016
DESCRIPTIONUS5776688
DESCRIPTIONUS5876930
DESCRIPTIONUS6277569
DESCRIPTIONUS7244567
DESCRIPTIONWO2007008724
DESCRIPTIONWO8601533
DESCRIPTIONWO8702671
DESCRIPTIONWO8809810
DESCRIPTIONWO8910134
DESCRIPTIONWO9002809
DESCRIPTIONWO9117271
DESCRIPTIONWO9201047
DESCRIPTIONWO9209690
DESCRIPTIONWO9215679
DESCRIPTIONWO9218619
DESCRIPTIONWO9220791
DESCRIPTIONWO9301288
DESCRIPTIONWO9416101
DESCRIPTIONWO9421822
INTERNATIONAL-SEARCH-REPORTUS2010130527
INTERNATIONAL-SEARCH-REPORTUS2011003298
INTERNATIONAL-SEARCH-REPORTUS2011118298
INTERNATIONAL-SEARCH-REPORTUS2012208706
OPPOSITIONEP2428508
OPPOSITIONEP2599878
OPPOSITIONEP2740742
OPPOSITIONKR20040075272
OPPOSITIONWO2005051308
OPPOSITIONWO2007087245
OPPOSITIONWO2010006432
OPPOSITIONWO2010128659
OPPOSITIONWO2012014795
OPPOSITIONWO2013018882
SEARCHEP2599878
SEARCHKR20040075272
SEARCHWO2007087245

Non-Patent Literature (NPL) Citations (82) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Anonymous, "Protein kinase inhibitor - Wikipedia", Wikipedia, (20110805), URL: https://en.wikipedia.org/w/index.php?title=Protein_kinase_inhibitor&oldid=443233351, (20170316), XP055355535
OPPOSITION- Advances in nucleic acid therapeutics, (20190000), ISBN 978-1-78801-571-4
OPPOSITION- ARIGHI et al., Cytokine and Growth Factor Reviews, (20050000), vol. 16, no. 4-5, pages 441 - 467
OPPOSITION- ARIGHI et al., Cytokine and Growth Factor Reviews, (20050000), vol. 16, no. 4-5, pages 441 - 467, XP027682307
OPPOSITION- Assignment for US 15/045716
OPPOSITION- Assignment of US 61/526613
OPPOSITION- Assignment of US 61/537024
OPPOSITION- Assignment of US 61/542112
OPPOSITION- Assignment of US 61/594739
OPPOSITION- AZANZA et al., "comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia", Int J Clin Pharmacol Pharmacother, (20180000), vol. 3, page 134
OPPOSITION- BEAUDRY et al., Molecular Cancer Therapeutics, (20080000), vol. 7, no. 2, pages 418 - 424
OPPOSITION- BRONTE et al., "targeting RET rearranged non-small cell lung cancer future prospects", LCTT, (20190000), vol. 10, pages 27 - 36
OPPOSITION- CARLOMAGNO et al., Cancer Research, (20020000), vol. 62, no. 24, pages 7284 - 7290
OPPOSITION- CARLOMAGNO et al., Cancer Research, (20020000), vol. 62, no. 24, pages 7284 - 7290, XP003011914
OPPOSITION- certified translation of EP 2740742's priority application
OPPOSITION- CHEN et al., "small molecule inhibitor regoraenib inhibits ret signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo", Oncotarget, (20170000), vol. 8, no. 61, pages 104090 - 104103
OPPOSITION- Declaration by Dr Haluk Tezan
OPPOSITION- Drilon et al, Cancer Discovery, (20130000), vol. 3, pages 630 - 635
OPPOSITION- DrugBank excerpts for axitinib (a), bosutinib (b), cediranib (c), dasatinib (d), and erlotinib (e
OPPOSITION- EMEA, "Scientific Discussion", TASIGNATM, (2007), XP055632132
OPPOSITION- FERRARA et al., "clinical and translational implications of ret rearrangements in non-small cell lung cancer", J Thoracic Oncol, (20180000), vol. 13, pages 27 - 45
OPPOSITION- Gainor and Shaw, Cancer Discovery, (20130000), vol. 3, pages 604 - 606
OPPOSITION- GAUTSCHI et al., "targeting RET in patients with RET Rearranged lung cancers results from the global multicenter RET registry", Clin Oncol, (20170000), vol. 35, pages l403 - 1410
OPPOSITION- HORIIKE et al., "Sorafenib treatment for patients withRETfusion-positive non-small cell lung cancer", Lung Cancer, (20160000), vol. 93, pages 43 - 46
OPPOSITION- JU et al., "A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing", Genome Res, (20120000), vol. 22, pages 436 - 45
OPPOSITION- JU et al., "A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing", Genome Research vol., (20110000), vol. 22, pages 436 - 445
OPPOSITION- KIF5B-ALK COSF1059 COSMIC entry
OPPOSITION- KIF5B-RET COSF1233 COSMIC entry
OPPOSITION- KOHNO et al., "KIF5B-RET fusions in lung adenocarcinoma", Nature Medicine, (20120000), vol. 18, no. 3, pages 375 - 377
OPPOSITION- LEE et al., "vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring ret rearrangement a phase ii clinical trial", Annals of Oncology, (20160000), vol. 28, pages 292 - 297
OPPOSITION- LIPSON et al., "Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies", Nature Medicine, (20120000), vol. 18, no. 3, pages 382 - 384
OPPOSITION- MAHER et al., "Chimeric transcript discovery by paired-end transcriptome sequencing", PNAS USA, (20090000), vol. 106, pages 12353 - 8
OPPOSITION- MEYERSON, "broken genes in solid tumours", Nature, (20070000), vol. 448, pages 545 - 6
OPPOSITION- MEYERSON, "broken genes in solid tumours", Nature, (20070000), vol. 448, pages 545 - 6, XP055632177
OPPOSITION- OKAMOTO et al., "Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models", Cancer Letters, (20130000), vol. 340, no. 1, pages 97 - 103
OPPOSITION- "Protein kinase inhibitor", wikipedia, (20150805), XP055355535
OPPOSITION- SCHOEBERL et al., "An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation", Cancer Res, (20100000), vol. 70, pages 2485 - 94
OPPOSITION- SHUM et al., "noncoding oligonucleotides the belle of the ball in gene therapy", Advances in Genetics, (20150000), vol. 89
OPPOSITION- Soda et al, Nature, (20070000), vol. 448, pages 561 - 566
OPPOSITION- SOMAIAH et al., "molecular targeted agents and biologic therapies for non-small cell lung cancer", Journal of Thoracic Oncology, (20100000), vol. 5, no. 12
OPPOSITION- SONG, "Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer", Journal Of Medicinal Chemistry, (20150000), vol. 58, no. 9, pages 3672 - 3681
OPPOSITION- TAKEUCHI, "discovery stories of RET fusions in lung cancer a mini review", Front Physiol, (20190000), vol. 10, page 216
OPPOSITION- TAKEUCHI et al., "KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer", Clinical Cancer Research, (20090000), vol. 15, no. 9, pages 3143 - 3149
OPPOSITION- TAKEUCHI et al., "RET, ROS1 and ALK fusions in lung cancer", Nature Medicine, (20120000), vol. 18, no. 3, pages 378 - 381
OPPOSITION- ULAHANNAN et al., "Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer", Cancer Investigation, (20110000), vol. 29, no. 4, pages 325 - 337
OPPOSITION- Wang et al, Medicine, (20190000), vol. 98, no. 3
OPPOSITION- "What is Bronchogenic Carcinoma?", inogen, (20180820), URL: www.inogen.com
OPPOSITION- "What is Bronchogenic Carcinoma?", inogen, (20180820), URL: www.inogen.com, XP055556171
OPPOSITION- Yoh et al, Lancet Respir. Med., (20170000), vol. 5, pages 42 - 50
OPPOSITION- YOKOTA, "KIF5B/RET fusion gene in surgically treated adenocarcinoma of lung", Oncology Reports, (20120000), vol. 28, pages 1 187 - 1192
OPPOSITION- ZABALLOS et al., "Key signaling pathways in thyroid cancer", Journal of Endocrinology, (20170000), vol. 235, pages R43 - R61
OPPOSITION- SHUM et al., "noncoding oligonucleotides the belle of the ball in gene therapy", Advances in Genetics, (20150000), vol. 89, XP055632109
OPPOSITION- OKAMOTO et al., "Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models", Cancer Letters, (20130000), vol. 340, no. 1, pages 97 - 103, XP028731370
OPPOSITION- FERRARA et al., "clinical and translational implications of ret rearrangements in non-small cell lung cancer", J Thoracic Oncol, (20180000), vol. 13, pages 27 - 45, XP055632126
OPPOSITION- HORIIKE et al., "Sorafenib treatment for patients withRETfusion-positive non-small cell lung cancer", Lung Cancer, (20160000), vol. 93, pages 43 - 46, XP029423005
OPPOSITION- SONG, "Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer", Journal Of Medicinal Chemistry, (20150000), vol. 58, no. 9, pages 3672 - 3681, XP055193521
OPPOSITION- KOHNO et al., "KIF5B-RET fusions in lung adenocarcinoma", Nature Medicine, (20120000), vol. 18, no. 3, pages 375 - 377, XP055145929
OPPOSITION- TAKEUCHI et al., "RET, ROS1 and ALK fusions in lung cancer", Nature Medicine, (20120000), vol. 18, no. 3, pages 378 - 381, XP055077341
OPPOSITION- LIPSON et al., "Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies",", Nat Med, (20120000), vol. 18, no. 3, pages 382 - 4, XP055145920
OPPOSITION- LIPSON et al., "Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies", Nature Medicine, (20120000), vol. 18, no. 3, pages 382 - 384, XP055145920
OPPOSITION- MAHER et al., "Chimeric transcript discovery by paired-end transcriptome sequencing", PNAS USA, (20090000), vol. 106, pages 12353 - 8, XP002606464
OPPOSITION- LEE et al., "vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring ret rearrangement a phase ii clinical trial", Annals of Oncology, (20160000), vol. 28, pages 292 - 297, XP055632028
OPPOSITION- SOMAIAH et al., "molecular targeted agents and biologic therapies for non-small cell lung cancer", Journal of Thoracic Oncology, (20100000), vol. 5, no. 12, XP055632092
OPPOSITION- JU et al., "A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing", Genome Res, (20120000), vol. 22, pages 436 - 45, XP055145939
OPPOSITION- JU et al., "A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing", Genome Research vol., (20110000), vol. 22, pages 436 - 445, XP003031534
OPPOSITION- SCHOEBERL et al., "An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation", Cancer Res, (20100000), vol. 70, pages 2485 - 94, XP002581703
OPPOSITION- TAKEUCHI et al., "KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer", Clinical Cancer Research, (20090000), vol. 15, no. 9, pages 3143 - 3149, XP055069999
OPPOSITION- BEAUDRY et al., Molecular Cancer Therapeutics, (20080000), vol. 7, no. 2, pages 418 - 424, XP055193451
OPPOSITION- GAUTSCHI et al., "targeting RET in patients with RET Rearranged lung cancers results from the global multicenter RET registry", Clin Oncol, (20170000), vol. 35, pages l403 - 1410, XP055632115
OPPOSITION- ZABALLOS et al., "Key signaling pathways in thyroid cancer", Journal of Endocrinology, (20170000), vol. 235, pages R43 - R61, XP055632083
OPPOSITION- AZANZA et al., "comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia", Int J Clin Pharmacol Pharmacother, (20180000), vol. 3, page 134, XP055632165
OPPOSITION- CHEN et al., "small molecule inhibitor regoraenib inhibits ret signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo", Oncotarget, (20170000), vol. 8, no. 61, pages 104090 - 104103, XP055632038
OPPOSITION- BRONTE et al., "targeting RET rearranged non-small cell lung cancer future prospects", LCTT, (20190000), vol. 10, pages 27 - 36, XP055632130
OPPOSITION- ULAHANNAN et al., "Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer", Cancer Investigation, (20110000), vol. 29, no. 4, pages 325 - 337, XP055192118
OPPOSITION- TAKEUCHI, "discovery stories of RET fusions in lung cancer a mini review", Front Physiol, (20190000), vol. 10, page 216, XP055632185
OPPOSITION- YOKOTA, "KIF5B/RET fusion gene in surgically treated adenocarcinoma of lung", Oncology Reports, (20120000), vol. 28, pages 1 187 - 1192, XP055632098
SEARCH- ARIGHI E ET AL, "RET tyrosine kinase signaling in development and cancer", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 16, no. 4-5, ISSN 1359-6101, (20050801), pages 441 - 467, (20050801), XP027682307 [X] 1,7,8,15-19 * the whole document * [I] 1-19
SEARCH- CARLOMAGNO F ET AL, "ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinase", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20021215), vol. 62, no. 24, ISSN 0008-5472, pages 7284 - 7290, XP003011914 [X] 1,7,8,15-19 * the whole document * [I] 1-19
SEARCH- OKAMOTO KIYOSHI ET AL, "Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models", CANCER LETTERS, (20130712), vol. 340, no. 1, doi:10.1016/J.CANLET.2013.07.007, ISSN 0304-3835, pages 97 - 103, XP028731370 [T] * the whole document *
SEARCH- MINSOO SONG, "Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer", JOURNAL OF MEDICINAL CHEMISTRY, (20150127), vol. 58, no. 9, doi:10.1021/jm501464c, ISSN 0022-2623, pages 3672 - 3681, XP055193521 [T] * the whole document *
SEARCH- P. BEAUDRY ET AL, "Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium", MOLECULAR CANCER THERAPEUTICS, (20080201), vol. 7, no. 2, doi:10.1158/1535-7163.MCT-07-0568, ISSN 1535-7163, pages 418 - 424, XP055193451 [X] 1 * the whole document *
SEARCH- SUSANNA V. ULAHANNAN ET AL, "Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer", CANCER INVESTIGATION, (20110406), vol. 29, no. 4, doi:10.3109/07357907.2011.554476, ISSN 0735-7907, pages 325 - 337, XP055192118 [X] 1 * the whole document * * page 330 - page 332; table 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents